The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Androgen receptors in endocrine‐therapy‐resistant human prostate cancer
Abstract
Despite the initial androgen‐dependent growth of most human prostate cancers, eventually all prostate cancers become androgen‐independent at varying intervals after androgen ablation or anti‐androgen therapy. In order to gain more insight into the role of the androgen receptor (AR) in this process, AR and prostate‐specific antigen (PA) expression was evaluated immunohistochemically in prostatic tumour tissues from patients who developed urinary flow obstruction between 4 and 107 months after onset of treatment. AR expression was evaluated with a monoclonal antibody (MAb) specific for the N‐ terminal domain of the human AR. To substantiate the progressive tumour growth, proliferative activity was assessed immunohistochemically by staining with MAb Ki‐67. Ki‐67‐defined tumour‐growth fractions varied from 0.8–64.7%. In 13 of the 17 examined tumours over 80% of the tumour cells were AR‐positive, 3 tumours showed a considerable heterogeneity in AR expression and in I tumour almost all tumour cells seemed to be AR‐negative. Two‐thirds of the examined tumours contained variable proportions of PA‐positive tumour areas. These observations contrast with the view that androgen ablation induces a preferential outgrowth of receptor‐negative tumour cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J.-A., Higgs, H. N., Larson, R. E., French, F. S., & Wilson, E. M. (1988) · Molecular Endocrinology · doi:10.1210/mend-2-12-1265 · Cited by 570
Autologous Down-Regulation of Androgen Receptor Messenger Ribonucleic Acid
Quarmby, V. E., Yarbrough, W. G., Lubahn, D. B., French, F. S., & Wilson, E. M. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-1-22 · Cited by 268
Use of human prostate-specific antigen in monitoring prostate cancer.
Kuriyama, M., Wang, M. C., Lee, C., Papsidero, L. D., Killian, C. S., Inaji, H., Slack, N. H., Nishiura, T., Murphy, G. P., & Chu, T. M. (1981) · PubMed · Cited by 192
Isaacs, J. T., Wake, N., Coffey, D. S., & Sandberg, A. A. (1982) · PubMed · Cited by 165
Veldscholte, J., Voorhorst-Ogink, M. M., Bolt-de Vries, J., van Rooij, H. C. J., Trapman, J., & Mulder, E. (1990) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(90)90075-o · Cited by 162
Self-citationCharacterization of the Prostate-specific Antigen gene: A novel human kallikrein-like gene
Riegman, P. H. J., Vlietstra, R. J., van der Korput, J. A. G. M., Romijn, J. C., & Trapman, J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92409-1 · Cited by 160
Self-citationRundlett, S. E., Wu, X.-P., & Miesfeld, R. L. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-5-708 · Cited by 138
Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry
de Winter, J. A. R., Trapman, J., Brinkmann, A. O., Boersma, W. J. A., Mulder, E., Schroeder, F. H., Claassen, E., & van der Kwast, T. (1990) · The Journal of Pathology · doi:10.1002/path.1711600409 · Cited by 106
Self-citationZegers, N. D., Claassen, E., Neelen, C., Mulder, E., van Laar, J. H., Voorhorst, M. M., Berrevoets, C., Brinkmann, A. O., van der Kwast, T., de Winter, J. A. R., et al. (1991) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(91)90178-j · Cited by 103
Self-citation
Cited by
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Nelson, W. G., De Marzo, A. M., & Isaacs, W. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021562 · Cited by 918
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Molecular genetics of prostate cancer
Abate-Shen, C., & Shen, M. M. (2000) · Genes & Development · doi:10.1101/gad.819500 · Cited by 735
Biology of Prostate-Specific Antigen
Balk, S. P., Ko, Y.-J., & Bubley, G. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.083 · Cited by 718
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer
Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548
Androgen receptor signaling in prostate cancer development and progression
Tindall, D., & Lonergan, P. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 535
Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-10-1396 · Cited by 523
Self-citationUpregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Wu, H., Hsieh, J., Gleave, M. E., Brown, N. M., Pathak, S., & Chung, L. W. K. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570319 · Cited by 499
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429
Androgen receptor gene mutations in human prostate cancer.
Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., & Barrack, E. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6319 · Cited by 419
Bonkhoff, H., & Remberger, K. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199602)28:2<98::aid-pros4>3.0.co;2-j · Cited by 416
Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690684 · Cited by 409
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
Tan, J.-A. (1997) · Molecular Endocrinology · doi:10.1210/me.11.4.450 · Cited by 375
(1994) · PubMed Central · Cited by 328
Regulation of prostatic growth and function by peptide growth factors
Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., & Klocker, H. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199606)28:6<392::aid-pros9>3.0.co;2-c · Cited by 307
Androgen receptor signaling in prostate cancer
Culig, Z., & Santer, F. R. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9474-0 · Cited by 283
Nuclear import of the human androgen receptor
Jenster, G., Trapman, J., & Brinkmann, A. O. (1993) · Biochemical Journal · doi:10.1042/bj2930761 · Cited by 273
Self-citationAndrogen receptor as a target in androgen-independent prostate cancer
Balk, S. P. (2002) · Urology · doi:10.1016/s0090-4295(02)01593-5 · Cited by 264
Interleukin-6 and prostate cancer progression
SMITH, P., HOBISCH, A., LIN, D., CULIG, Z., & KELLER, E. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00021-6 · Cited by 264
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Massie, C. E., Adryan, B., Barbosa‐Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., & Mills, I. G. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401046 · Cited by 259
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143
Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells.
Nadiminty, N., Lou, W., Sun, M., Chen, J., Yue, J., Kung, H.-J., Evans, C. P., Zhou, Q., & Gao, A. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3703 · Cited by 113
Castration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas
Bonkhoff, H., Stein, U., Aumüller, G., & REMBERGER, K. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199610)29:4<261::aid-pros7>3.0.co;2-e · Cited by 116
Androgen receptor decoy molecules block the growth of prostate cancer.
Quayle, S. N., Mawji, N. R., Wang, J., & Sadar, M. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606718104 · Cited by 84
Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells
Park, S.-Y., Kim, Y.-J., Gao, A. C., Mohler, J. L., Onate, S. A., Hidalgo, A. A., Ip, C., Park, E.-M., Yoon, S. Y., & Park, Y.-M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1341 · Cited by 81
Androgen Receptor Mutations in Carcinoma of the Prostate: Significance for Endocrine Therapy
Culig, Z., Klocker, H., Bartsch, G., & Hobisch, A. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101040-00001 · Cited by 50
Gazi, M. H., Gong, A., Donkena, K. V., & Young, C. Y. F. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.031 · Cited by 19
Metadata
- Authors
- van der Kwast, T. H., Schalken, J., de Winter, J. A. R., van Vroonhoven, J. C. C., Mulder, E., Boersma, W., & Trapman, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1991-05-10
- Volume
- 48
- Issue
- 2
- Pages
- 189-193
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2008498145
- Cited by
- 386
- References
- 17
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.